NCT04620473

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal cancer-a Prospective, Open, Single Center and Randomized Controlled Phase Ⅱ Clinical Trial

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Shanghai Minimally Invasive Surgery Center · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Prospectively Investigate the effectiveness and safety of anlotinib hydrochloride combined with Capeox in neoadjuvant treatment of patients with locally advanced rectal cancer.

Conditions

• Neoadjuvant Treatment
• Rectal Cancer
• Anlotinib

Interventions

Type	Name	Description
DRUG	Anlotinib+Capeox	to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
DRUG	Capeox	to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer

Timeline

• Start date: 2023-11-01
• Primary completion: 2023-12-01
• Completion: 2024-10-01
• First posted: 2020-11-09
• Last updated: 2021-09-28